C-Reactive Protein, Inflammatory Conditions, and Cardiovascular Disease Risk

American Journal of Medicine

Volumn 120, Issue 12, 2007, Pages 1054-1062

  Dhingra, Ravi ^a,b,c   Gona, Philimon ^a,d   Nam, Byung Ho ^a,d   D'Agostino Sr , Ralph B ^a,d   Wilson, Peter W F ^a,e   Benjamin, Emelia J ^a,f   O'Donnell, Christopher J ^a,g,h  

^a FRAMINGHAM HEART STUDY   (United States)

^b Alice Peck Day Memorial Hospital   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Boston University   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Arthritis; C reactive protein; Cardiovascular disease; Cohort study; Inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; EVALUATION; FEMALE; HUMAN; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; UNITED STATES;

EID: 36448934528     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.08.037     Document Type: Article

References (40)

1. Koenig W., Sund M., Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
2. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
3. Wang T.J., Nam B.H., Wilson P.W., et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22 (2002) 1662-1667
4. Wang T.J., Larson M.G., Levy D., et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women: the Framingham Heart Study. Circulation 106 (2002) 1189-1191
5. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
6. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32 (2001) 2575-2579
7. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
8. Wilson P.W., Nam B.H., Pencina M., et al. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165 (2005) 2473-2478
9. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
10. Ford E.S. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 22 (1999) 1971-1977
11. Sesso H.D., Buring J.E., Rifai N., et al. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
12. Bazzano L.A., He J., Muntner P., et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138 (2003) 891-897
13. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
14. Carlson C.S., Aldred S.F., Lee P.K., et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 77 (2005) 64-77
15. Kathiresan S., Larson M.G., Vasan R.S., et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 113 (2006) 1415-1423
16. Macy E.M., Hayes T.E., and Tracy R.P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43 (1997) 52-58
17. Khera A., McGuire D.K., Murphy S.A., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46 (2005) 464-469
18. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46 (2002) 328-346
19. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 50 (2004) 2423-2427
20. Mannino D.M., Ford E.S., and Redd S.C. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 114 (2003) 758-762
21. Kushner I., Rzewnicki D., and Samols D. What does minor elevation of C-reactive protein signify?. Am J Med 119 (2006) 166.e17-166.e28
22. Anderson N.L., and Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1 (2002) 845-867
23. Pepys M.B., and Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34 (1983) 141-212
24. Zimmerman M.A., Selzman C.H., Cothren C., et al. Diagnostic implications of C-reactive protein. Arch Surg 138 (2003) 220-224
25. Myers G.L., Rifai N., Tracy R.P., et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 110 (2004) e545-e549
26. Kannel W.B., Feinleib M., McNamara P.M., et al. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 110 (1979) 281-290
27. In: Kannel W.B., Wolf P.A., and Garrison R.J. (Eds). The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Section 34. Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements: Framingham Heart Study, 30-year follow up (1987), National Heart, Lung and Blood Institute, Bethesda, MD (NIH publication no. 87-2703)
28. Lloyd-Jones D.M., Nam B.H., D'Agostino Sr. R.B., et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 291 (2004) 2204-2211
29. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
30. Hosmer D.W., and Lemeshow S. Applied Logistic Regression (1989), John Wiley and Sons, Inc, New York, NY
31. Cochran W.G. The comparison of percentages in matched samples. Biometrika 37 (1950) 256-266
32. Koenig W. C-reactive protein and cardiovascular risk: has the time come for screening the general population?. Clin Chem 47 (2001) 9-10
33. Mosca L. C-reactive protein-to screen or not to screen?. N Engl J Med 347 (2002) 1615-1617
34. Goodson N.J., Symmons D.P., Scott D.G., et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 52 (2005) 2293-2299
35. Pasceri V., and Yeh E.T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100 (1999) 2124-2126
36. Cermak J., Key N.S., Bach R.R., et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 (1993) 513-520
37. Nakagomi A., Freedman S.B., and Geczy C.L. Interferon-{gamma} and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 101 (2000) 1785-1791
38. Hirschfield G.M., Gallimore J.R., Kahan M.C., et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 102 (2005) 8309-8314
39. Pepys M.B., Hawkins P.N., Kahan M.C., et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 97 (2005) e97-e103
40. Clarke J.L., Anderson J.L., Carlquist J.F., et al. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol 95 (2005) 155-158